Oncocyte Corporation/$IMDX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Oncocyte Corporation
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx.
Ticker
$IMDX
Sector
Primary listing
Employees
48
Headquarters
Website
IMDX Metrics
BasicAdvanced
$69M
-
-$2.85
1.05
-
Price and volume
Market cap
$69M
Beta
1.05
52-week high
$4.75
52-week low
$2.33
Average daily volume
40K
Financial strength
Current ratio
4.035
Quick ratio
3.728
Long term debt to equity
167.031
Total debt to equity
307.286
Interest coverage (TTM)
-215.27%
Profitability
EBITDA (TTM)
-22.803
Gross margin (TTM)
55.70%
Net profit margin (TTM)
-1,489.71%
Operating margin (TTM)
-581.54%
Revenue per employee (TTM)
$90,000
Management effectiveness
Return on assets (TTM)
-24.71%
Return on equity (TTM)
-532.89%
Valuation
Price to revenue (TTM)
12.53
Price to book
62.55
Price to tangible book (TTM)
-5.09
Price to free cash flow (TTM)
-2.223
Free cash flow yield (TTM)
-44.99%
Free cash flow per share (TTM)
-1.08
Growth
Revenue change (TTM)
316.13%
Earnings per share change (TTM)
-26.97%
3-year revenue growth (CAGR)
132.43%
3-year earnings per share growth (CAGR)
-41.22%
10-year earnings per share growth (CAGR)
-6.22%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Oncocyte Corporation stock?
Oncocyte Corporation (IMDX) has a market cap of $69M as of August 18, 2025.
What is the P/E ratio for Oncocyte Corporation stock?
The price to earnings (P/E) ratio for Oncocyte Corporation (IMDX) stock is 0 as of August 18, 2025.
Does Oncocyte Corporation stock pay dividends?
No, Oncocyte Corporation (IMDX) stock does not pay dividends to its shareholders as of August 18, 2025.
When is the next Oncocyte Corporation dividend payment date?
Oncocyte Corporation (IMDX) stock does not pay dividends to its shareholders.
What is the beta indicator for Oncocyte Corporation?
Oncocyte Corporation (IMDX) has a beta rating of 1.05. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.